Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 7;6(1):e008928.
doi: 10.1136/bmjopen-2015-008928.

What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study

Suzanne Parsons  1 , Bella Starling  1 , Christine Mullan-Jensen  2 , Su-Gwan Tham  3 , Kay Warner  4 , Kim Wever  5
Affiliations

What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study

Suzanne Parsons et al. BMJ Open. .

Abstract

Objectives: To explore European-based pharmaceutical industry professionals' beliefs about patient and public involvement (PPI) in medicines research and development (R&D).

Setting: Pharmaceutical companies in the UK, Poland and Spain.

Participants: 21 pharmaceutical industry professionals, four based in the UK, five with pan-European roles, four based in Spain and eight based in Poland.

Method: Qualitative interview study (telephone and face-to-face, semistructured interviews). All interviews were audio taped, translated (where appropriate) and transcribed for analysis using the Framework approach.

Results: 21 pharmaceutical industry professionals participated. Key themes were: beliefs about (1) whether patients and the public should be involved in medicines R&D; (2) the barriers and facilitators to PPI in medicines R&D and (3) how the current relationships between the pharmaceutical industry, patient organisations and patients influence PPI in medicines R&D.

Conclusions: Although interviewees appeared positive about PPI, many were uncertain about when, how and which patients to involve. Patients and the public's lack of knowledge and interest in medicines R&D, and the pharmaceutical industry's lack of knowledge, interest and receptivity to PPI were believed to be key challenges to increasing PPI. Interviewees also believed that relationships between the pharmaceutical industry, patient organisations, patients and the public needed to change to facilitate PPI in medicines R&D. Existing pharmaceutical industry codes of practice and negative media reporting of the pharmaceutical industry were also seen as negative influences on these relationships.

Keywords: PUBLIC HEALTH; QUALITATIVE RESEARCH; SOCIAL MEDICINE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmaceutical industry professionals' views on the influences on patient involvement in medicines research and development. R&D, research and development.
See this image and copyright information in PMC

References

    1. Coulter A, Askham J, Parsons S. Where are the patients in decision making about their own care? WHO Regional Office for Europe, 2008:1–14.
    1. Nelson EC, Eftimovska E, Lind C et al. . Patient reported outcome measures in practice. BMJ 2015;350:g7818 10.1136/bmj.g7818 - DOI - PubMed
    1. Coulter A, Locock L, Ziebland S et al. . Collecting data on patient experience is not enough: they must be used to improve care. BMJ 2014;348:g2225 10.1136/bmj.g2225 - DOI - PubMed
    1. Boote J, Wong R, Booth A. ‘Talking the talk or walking the walk?’ A bibliometric review of the literature on public involvement in health research published between 1995 and 2009. Health Expect 2015;18:44–57. 10.1111/hex.12007 - DOI - PMC - PubMed
    1. Moors E, Cohen AF, Schellekens H. Towards a sustainable system of drug development. Drug Discov Today 2014;19:1711–20. 10.1016/j.drudis.2014.03.004 - DOI - PubMed

Publication types